116 related articles for article (PubMed ID: 34509346)
1. Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
Duffaud F; Schiffler C; Chabaud S; Blay JY
Eur J Cancer; 2021 Nov; 157():527-528. PubMed ID: 34509346
[No Abstract] [Full Text] [Related]
2. Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.
Zhou D; Connolly E; Strach M; Bhadri V; Grimison P
Eur J Cancer; 2021 Nov; 157():525-526. PubMed ID: 34509345
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.
Duffaud F; Italiano A; Bompas E; Rios M; Penel N; Mir O; Piperno-Neumann S; Chevreau C; Delcambre C; Bertucci F; Boudou-Rouquette P; Cancel M; Perrin C; Saada-Bouzid E; Monard L; Schiffler C; Chaigneau L; Hervieu A; Collard O; Bouvier C; Vidal V; Chabaud S; Blay JY;
Eur J Cancer; 2021 Jun; 150():108-118. PubMed ID: 33895682
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.
Mir O; Brodowicz T; Italiano A; Wallet J; Blay JY; Bertucci F; Chevreau C; Piperno-Neumann S; Bompas E; Salas S; Perrin C; Delcambre C; Liegl-Atzwanger B; Toulmonde M; Dumont S; Ray-Coquard I; Clisant S; Taieb S; Guillemet C; Rios M; Collard O; Bozec L; Cupissol D; Saada-Bouzid E; Lemaignan C; Eisterer W; Isambert N; Chaigneau L; Cesne AL; Penel N
Lancet Oncol; 2016 Dec; 17(12):1732-1742. PubMed ID: 27751846
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study.
Le Cesne A; Chevreau C; Perrin C; Italiano A; Hervieu A; Blay JY; Piperno-Neumann S; Saada-Bouzid E; Bertucci F; Firmin N; Kalbacher E; Narciso B; Schiffler C; Yara S; Jimenez M; Bouvier C; Vidal V; Chabaud S; Duffaud F
ESMO Open; 2023 Jun; 8(3):101569. PubMed ID: 37285716
[TBL] [Abstract][Full Text] [Related]
8. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib.
Penel N; Mir O; Wallet J; Ray-Coquard I; Le Cesne A; Italiano A; Salas S; Delcambre C; Bompas E; Bertucci F; Saada-Bouzid E; Chaigneau L; Chevreau C; Brodowicz T; Decoupigny E; Vanseymortier M; Laroche L; Taieb S; Le Deley MC; Blay JY
Eur J Cancer; 2020 Feb; 126():45-55. PubMed ID: 31918233
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.
Duffaud F; Blay JY; Le Cesne A; Chevreau C; Boudou-Rouquette P; Kalbacher E; Penel N; Perrin C; Laurence V; Bompas E; Saada-Bouzid E; Delcambre C; Bertucci F; Cancel M; Schiffler C; Monard L; Bouvier C; Vidal V; Gaspar N; Chabaud S
Br J Cancer; 2023 Dec; 129(12):1940-1948. PubMed ID: 37914801
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.
Pavlakis N; Sjoquist KM; Martin AJ; Tsobanis E; Yip S; Kang YK; Bang YJ; Alcindor T; O'Callaghan CJ; Burnell MJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Wong M; Strickland A; Kim JW; Zalcberg JR; Simes J; Goldstein D
J Clin Oncol; 2016 Aug; 34(23):2728-35. PubMed ID: 27325864
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A; Van Cutsem E; Sobrero A; Siena S; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Tabernero J; Yoshino T; Lenz HJ; Goldberg RM; Sargent DJ; Cihon F; Cupit L; Wagner A; Laurent D;
Lancet; 2013 Jan; 381(9863):303-12. PubMed ID: 23177514
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402).
Tanioka H; Miyamoto Y; Tsuji A; Asayama M; Shiraishi T; Yuki S; Kotaka M; Makiyama A; Shimokawa M; Shimose T; Masuda S; Yamaguchi T; Komatsu Y; Saeki H; Emi Y; Baba H; Oki E; Maehara Y;
Oncology; 2018; 94(5):289-296. PubMed ID: 29514163
[TBL] [Abstract][Full Text] [Related]
14. Topical administration of regorafenib eye drops: phase I dose-escalation study in healthy volunteers.
Zimmermann T; Höchel J; Becka M; Boettger MK; Rohde B; Schug B; Kunert KS; Donath F
Br J Clin Pharmacol; 2018 May; 84(5):865-875. PubMed ID: 29315699
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis.
Abrahao ABK; Ko YJ; Berry S; Chan KKW
Clin Colorectal Cancer; 2018 Jun; 17(2):113-120. PubMed ID: 29174481
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
17. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib in gastrointestinal stromal tumors.
Sirohi B; Philip DS; Shrikhande SV
Future Oncol; 2014; 10(9):1581-7. PubMed ID: 25145429
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
